ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients that creates science-based
solutions for dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products announced today that
it has appointed Dr. Rudolph Tanzi, Vice-Chair of Neurology
and Director of the Genetics and Aging Research Unit at
Massachusetts General Hospital, and the Joseph P. and Rose F.
Kennedy Professor of Neurology at Harvard Medical School, to the
Scientific Advisory Board (SAB).
ChromaDex’s Founder and CEO, Frank Jaksch,
stated, “Dr. Tanzi is a true pioneer in the fields of Alzheimer’s
research and Neurology. His expertise and scientific network will
be instrumental in helping to identify and execute opportunities to
study NIAGEN® nicotinamide riboside (NR) and its impact on brain
health.”
Dr. Tanzi, commented, “The studies that Dr.
Charles Brenner has published on NR have already created a great
deal of interest in the field of brain health and neurological
disease. I am very excited to now join forces with ChromaDex in
exploring the potential for NR in improving brain health and
overall wellness."
Tanzi received his B.S. (microbiology) and B.A.
(history) at the University of Rochester in 1980, and his Ph.D.
(neurobiology) at Harvard Medical School in 1990. His research
achievements include serving on the team that discovered the
Huntington’s, Wilson’s, and other such disease genes. He is
well-known as the co-discoverer of all three early-onset familial
Alzheimer’s disease genes, an area of study in which he continues
important work today.
Additionally, Tanzi has published over 500
research papers and received the highest awards in his field, as
well as the Smithsonian American Ingenuity Award, the top national
award for invention and innovation. He serves on various editorial
and scientific advisory boards and was named to TIME magazine’s
list of TIME100 Most Influential People in the World (2015). He
co-authored the popular trade books “Decoding Darkness,” a New York
Times bestseller, “Super Brain,” and international bestseller
“Super Genes”.
ChromaDex, President and Chief Strategy Officer,
Rob Fried said “We recognize the importance in working with the
world's best scientific minds to manage this important ingredient.
Dr. Tanzi, like all of our scientific advisors, is a big
believer in NIAGEN® and the work of Dr. Brenner.”
Head of the ChromaDex SAB, and Professor at
Stanford Medical School, Roger Kornberg, added, “As the portfolio
of science pertaining to NR and ChromaDex’s other ingredient
research expands into an ever-growing number of areas, so does the
strength and expertise of the members of our Scientific Advisory
Board. We are pleased to have yet another accomplished researcher
who is passionate about advancing the understanding of complex
scientific areas, as part of our team.”
ChromaDex, being publicly traded on NASDAQ,
gives the public an opportunity for investing in the business of
science-based technologies for healthy aging and longevity. To
date, ChromaDex has invested millions in safety, toxicology and
human clinical trials on Nicotinamide Riboside (NR). It has also
initiated over 100 collaborative studies with leading universities
and research institutions such as the National Institute of Aging,
MIT and the Scripps Research Institute representing an estimated
$50 million in NR research.
Nicotinamide adenine dinucleotide (NAD+) is an
essential coenzyme in cellular metabolism. Published research
suggests that many aging-related health challenges are linked to
NAD+ deficiency. NAD+ and its metabolites such as
Nicotinamide Riboside (NR) have been the focus of intense
scientific research and popular news media coverage recently due to
their believed roles in healthy aging and healthspan. NR has
been shown to safely and effectively increase NAD+ in human
subjects supported by published research in Nature
Communications.
For more information about ChromaDex, visit
www.chromadex.com.
About ChromaDex:ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary ingredient
technologies that address the dietary supplement, food, beverage,
skin care and pharmaceutical markets. In addition to our ingredient
technologies unit, we also have business units focused on natural
product fine chemicals (known as "phytochemicals"), chemistry and
analytical testing services, and product regulatory and safety
consulting. As a result of our relationships with leading
universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then
utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our
ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of
patented ingredient technologies includes NIAGEN® nicotinamide
riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and
AnthOrigin™, anthocyanins derived from a domestically-produced,
water-extracted purple corn husk. To learn more about ChromaDex,
please visit www.ChromaDex.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to expertise of Dr. Tanzi,
NR’s potential in brain and neuronal health, and results of the
NR studies and their significance. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2016,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024